Vertex Pharmaceuticals Acquires Crinetics Pharmaceuticals for $10 Billion
Vertex Pharmaceuticals has acquired Crinetics Pharmaceuticals in a $10 billion cash deal to diversify its portfolio beyond cystic fibrosis drugs. The acquisition grants Vertex access to Palsonify, an FDA-approved treatment for acromegaly and several pipeline candidates.
